Dyslipidemia Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: May 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 23.57 billion |
|
Revenue Forecast in 2031 |
US$ 32.40 billion |
|
CAGR |
3.6% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Disease type, Drug class, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global dyslipidemia drugs market was valued at US$ 23.57 billion in 2022 and is expected to register a revenue CAGR of 3.6% to reach US$ 32.40 billion by 2031.
Dyslipidemia Drugs Market Fundamentals
Dyslipidemia is described as abnormally high or low blood lipid levels. The term dyslipidemia refers to a variety of conditions, the most common of which include high levels of low-density lipoproteins (LDL), or bad cholesterol, low levels of high-density lipoproteins (HDL), or good cholesterol, high levels of triglycerides, and high cholesterol, which refers to high levels of LDL and triglyceride levels, lipids, or fats. Changing one's diet, in particular, can help decrease LDL cholesterol levels. Reducing trans-fat consumption is also an important step in decreasing cholesterol levels. Although statins, resins, fibrates, niacin, and combinations remain the most commonly used options for dyslipidemia pharmaceutical therapy. However, additional options are available in specific situations, such as PCSK9 inhibitors, the newly licensed control of microsomal triglyceride transfer protein, and antisense oligonucleotide drugs.
[12]
Dyslipidemia Drugs Market Dynamics
Irregular lifestyle with growing consumption of alcohol and tobacco is one of the major driving factors in the global dyslipidemia drugs market. Diet is the most important lifestyle factor that directly impacts health. A bad diet and its consequences, such as obesity, are common health concerns in urban societies. Additionally, urban life generates dietary concerns, such as the consumption of fast food and unhealthy meals, which raises the risk of illnesses such as cardiovascular disease and dyslipidemia. As a result of these high lipid levels, plaque (fatty deposits) forms in the arteries of the heart. Thus, the arteries stiffen and constrict, reducing blood flow and eventually leading to a heart attack or stroke. The market is expected to be pushed by emerging biotechnological products such as monoclonal antibodies for treating lipid illnesses, new lipid research methodologies, diagnostic advancements, etc. In addition, recent technological advancements that can also be utilized to analyze the content, structure, and localization of lipids have made it feasible to understand the function of major lipid molecules.
Additionally, new genome-sequencing data helps to understand the genetic diversity impacts of Dyslipidemia and functional follow-up in the lab using cellular and animal models that can be useful for designing therapies for the illness. Recent developments in genome editing technology have made it easier for researchers to explore how genetic variants impact disease processes, which can assist in informing the creation of treatments by employing CRISPR-Cas9-based genome editing technology. Numerous private and governmental organizations, as well as major corporations, are actively working to raise awareness of dyslipidemia by implementing various awareness campaigns or publishing guidelines for the condition.
Moreover, proprotein convertase subtilisin/kexin type 9 (PCSK9) has been a prominent mediator of low-density lipoprotein cholesterol (LDL-c) levels and, thus, a possible novel target for lowering the risk of coronary heart disease in recent biochemical and genetic research. The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9), which belongs to the subtilisin family, binds to the LDLR and promotes LDLR breakdown, resulting in decreased LDL sequestration and elevated levels of circulating LDL-C.
However, the high capital needs for biotechnology-based R&D medication development and the expiration of many enterprises' patents are expected to be significant impediments to the dyslipidemia market's expansion. Significant R&D expenditure and a continual supply of new ideas differentiate the worldwide dyslipidemia industry. Large multinational firms fund the majority of industry R&D with profits from exclusive rights, which can result in huge market domination and massive profit margins. As a result, the absence of enough financing to research novel strategies for dyslipidemia therapy has a detrimental influence on market expansion.
Dyslipidemia Drugs Market Ecosystem
The global dyslipidemia drugs market has been analyzed from the following perspectives: disease type, drug class, and region.
Dyslipidemia Drugs Market by Disease Type
[56]
Based on the disease types, the global dyslipidemia drugs market is segmented into pure hypercholesterolemia, pure hypertriglyceridemia, and pure hyperlipidemia.
The pure hypercholesterolemia segment accounts for a prominent revenue share in the global market. Hypercholesterolemia is defined as a high blood cholesterol level. Pure hypercholesterolemia can result from both hereditary and environmental causes. Familial/ pure hypercholesterolemia is a classic genetic condition caused by mutations in the low-density lipoprotein (LDL)-receptor gene, resulting in LDL-C levels greater than 190 mg/dl in heterozygotes and greater than 450 mg/dl in homozygotes. Familial hypercholesterolemia (FH) is a rare inherited disorder. It affects around one in every 250 people. This disease is caused by gene mutations that remove LDL cholesterol from the blood.
Furthermore, familial hypercholesterolemia is caused by loss-of-function mutations in the gene encoding the LDL receptor. Reduced LDL receptor activation in the liver causes a slower rate of LDL clearance from the bloodstream. The most frequent hypercholesterolemia is caused by a combination of unknown genetic factors, a sedentary lifestyle, and increased saturated and trans-fatty acid consumption.
The pure hypertriglyceridemia segment is also expected to account for a sizeable revenue share in the global market. Pure hypertriglyceridemia is characterized by an unusually high triglyceride content in the blood. Triglycerides are lipids (fats) that provide energy to the body. On the other hand, high triglyceride levels increase the risk of cardiovascular disease. The increased prevalence of cardiovascular disease and diabetes and a rise in government programs to promote a healthy lifestyle are driving the segment's growth. The two primary sources of plasma triglycerides (triacylglycerol) are exogenous (from dietary fat) and transported in chylomicrons. At the same time, the other is endogenous (from the liver) and carried in very low-density lipoprotein (VLDL) particles. Lipoprotein lipase hydrolyzes these lipoproteins and chylomicrons into free fatty acids in adipose and muscle tissue capillaries. Furthermore, hypertriglyceridemia is multifactorial, caused by a combination of genetic factors and other causes of increased synthesis and poor clearance of triglyceride-rich lipoproteins (TRLPs). A significant rise in triglycerides (TG) increases a person's risk of pancreatitis and demands lowering by lifestyle modifications and medication, as well as finding the underlying reason. Although statin therapy has improved outcomes in atherosclerotic cardiovascular disease (ASCVD), there is still a risk.
Dyslipidemia Drugs Market by Drug Class
Based on the drug class, the global dyslipidemia drugs market is segmented into bile acid resins, statins/3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitors, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, niacins, fabric acid & omega-3 fatty acid derivatives, and fixed-dose combination.
The bile acid resins segment dominates the global market with the largest revenue share. Bile acid resins, or sequestrants, are the oldest and safest lipid-lowering medications, although they are less powerful than other options and are not always well tolerated. Bile acid sequestrants are highly positively charged molecules that bind to negatively charged bile acids in the gut, inhibiting their lipid solubilizing activity and limiting cholesterol absorption. They also inhibit bile acid reabsorption (usually by 95%), creating a constriction of the bile acid pool, which leads to increased bile acid production, which competes with cholesterol synthesis in the liver, resulting in a reduction in blood cholesterol levels. In the United States, three bile acid sequestrants are available: cholestyramine (Questran), colesevelam (Welchol), and colestipol (Colestid). Due to their capacity to diminish the "pruritogens" that accumulate in cholestatic types of liver disease, these medicines are also used to treat pruritus. Ion-exchange resins are polymeric compounds that act as bile acid sequestrants. Bile acid sequestrants convert anions such as chloride ions into bile acids. They bind to bile acids and keep them out of the enterohepatic circulation.
Similarly, the statins segment also registers a significant revenue share, thus driving the overall growth of the global market. Statins have been used for almost 50 years as the first line of treatment for dyslipidemia, used to lower LDL-C levels and the cornerstone of treatment for high LDL-C levels. Although several statins should be equally effective in treating dyslipidemia, atorvastatin is the most widely used and prescribed. A moderate-intensity statin should drop LDL-C by 30% to less than 50%, whereas a high-intensity statin should lower LDL-C by more than or equal to 50%. High-intensity statins include atorvastatin 40 or 80 mg and rosuvastatin 20 mg. Atorvastatin 1 mg, rosuvastatin 10 mg, simvastatin 20 mg or 40 mg, pravastatin 10 mg, and other moderate-intensity statins are examples. Statin medications block hydroxymethylglutaryl CoA reductase, the rate-limiting enzyme in cholesterol formation, resulting in lower intrahepatic cholesterol, higher hepatic LDL receptor expression, and enhanced hepatic LDL absorption, which lowers blood LDL.
PCSK9 inhibitors segment is estimated to show rapid growth during the forecast period with a notable revenue share. PCSK9 inhibitors are biologically active chemicals that reduce LDL cholesterol levels in the blood compared to statin treatment alone. They are used as an alternative to statins in patients who are intolerant to statins or as an adjunct treatment in patients who do not reduce serum low-density lipoprotein cholesterol levels with statins alone. PCSK9 induces hypercholesterolemia by binding to LDL receptors on the surface of hepatocytes, where it is internalized and transported to lysosomes for degradation. There are now three FDA-approved monoclonal antibodies that block the action of PCSK9 in the United States: Alirocumab, Evolocumab, and Inclisiran.
Dyslipidemia Drugs Market by Region
Based on the region, the global dyslipidemia drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America registered the largest revenue share in the global market. Increased public awareness about the impact of dyslipidemia on overall health is leading to greater demand for diagnosis and treatment of dyslipidemia in North America. Combination therapies are becoming popular for managing dyslipidemia and reducing cardiovascular risk. Moreover, the rise in R&D related to the non-statins, such as ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, also propelled the growth of the market. The growing regional government and non-government initiatives promoting preventive healthcare and early detection and treatment of chronic conditions further drive demand for dyslipidemia treatments.
Additionally, sedentary lifestyles and cigarette use are increasing dyslipidemia in the population. In North America, healthcare practitioners increasingly emphasize the significance of patient education and lifestyle changes, such as exercise and food, in controlling dyslipidemia. Rising healthcare spending and insurance coverage make dyslipidemia therapies more accessible to patients, pushing growth in the North American market even further.
Dyslipidemia Drugs Market Competitive Landscape
The prominent players operating in the global dyslipidemia drugs market are:
The estimated market size of the global dyslipidemia drugs market in 2031 is US$ 32.40 billion.
The revenue CAGR for the dyslipidemia drugs market is 3.6% during the forecast period.
Regeneron Pharmaceuticals Inc., Sanofi S.A., Amgen Inc., and Pfizer Inc. are some of the major key players in the dyslipidemia drugs market.
The Asia Pacific region is projected to grow at high revenue CAGR in the global dyslipidemia drugs market.
The bile acid resins drug class segment dominates the global dyslipidemia drugs market.
*Insights on financial performance are subject to the availability of information in the public domain